Testing for cancer may soon be as simple as a pinprick. Researchers in the United Kingdom say they are developing a universal blood test to detect cancer. So far, the team from the University of Bradford has tested their lymphocyte genome sensitivity test on patients with melanoma, lung cancer and colon cancer.esting for cancer may soon be as simple as a pinprick. Researchers in the United Kingdom say they are developing a universal blood test to detect cancer. So far, the team from the University of Bradford has tested their lymphocyte genome sensitivity test on patients with melanoma, lung cancer and colon cancer.
Aicardi syndrome is a rare neurologic disorder first described by the French neurologist, Dr. Jean Aicardi, in 1965. It occurs almost exclusively in females (46,XX), however, it can also occur in males with Klinfelter Syndrome (47,XXY). A handful of reports in the literature exist of Aicardi syndrome in a normal male. Some of these reports have been disputed, and it is possible that these cases are caused by mosaic mutations of the Aicardi syndrome gene(s).
The most common cause of secondary imatinib resistance is point mutations in BCR-ABL that prevent effective binding of imatinib but may retain kinase activity. Over 100 point mutations coding for single amino acid substitutions in the BCR-ABL kinase domain have been isolated from imatinib resistant CML patients.he exchange of the amino acids threonine and isoleucine at position 315 (T315I) of the BCR-ABL protein was the first mutation detected in imatinib resistant chronic myeloid leukemia (CML) patients. Sequencing of cloning products revealed the T315I mutation in 6 of 9 resistant patients.